FDA supplemental approval: Naproxen Sodium (Labeling)

AI Summary

This is a U.S. FDA supplemental approval for labeling changes to naproxen sodium tablets (250 mg and 500 mg base equivalents), issued on 25 June 2026. The record indicates a regulatory action by the agency but does not report clinical trial outcomes, efficacy data, or safety findings.

Plain-language summary

FDA supplemental approval for naproxen sodium labeling; describes a regulatory action, not clinical evidence of efficacy or safety.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

This regulatory record does not provide clinical evidence on which to base treatment decisions. Clinicians should consult the updated product labeling and FDA-approved prescribing information for current guidance on indications, dosing, contraindications, and safety.

Caveats

• This record does not contain clinical trial results, efficacy data, or safety study outcomes.
• The specific nature of the labeling changes is not detailed in this submission record.
• No comparative effectiveness or safety data are provided.
• The record does not indicate whether this approval was based on new clinical evidence or administrative/manufacturing changes.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.